Sperling, Michael et al "A 12-month, open-label, repeat-dose safety study of Valtoco ™ (NRL-1, diazepam nasal spray) in patients with epilepsy: Interim report (P1.5-028)." Neurology 92.15 Supplement (2019): P1.5-028. Web. 04 Aug. 2020.